Background No pooled analysis has been undertaken to assess the efficacy and safety of
the non‐vitamin K antagonist oral anticoagulants (NOACs) compared with warfarin in the …

Objectives: This study investigated the efficacy and safety of novel oral anticoagulants
(NOACs) in patients with atrial fibrillation (AF) and heart failure (HF) by a meta-analysis …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …

Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Objective There has been limited systematic evaluation of outcomes and drivers of
inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients …

The non-vitamin K antagonist oral anticoagulants (NOACs) were approved for non-valvular
atrial fibrillation (AF) but this term may be misnomer. Thus, the term non-mechanical and …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …

Aims The aim of the present meta-analysis was to evaluate the efficacy and safety of non-
vitamin K oral antagonists (NOACs) vs. vitamin K antagonists (VKAs) in elderly patients with …

Aims In the ENGAGE AF‐TIMI 48 trial, edoxaban, a factor Xa inhibitor, was not found to be
inferior to warfarin for the prevention of stroke or systemic embolic events (SEE) in patients …